TNF and rheumatoid arthritis: Since response to treatment remains one of the biggest challenges in RA management, we next wondered about the ex vivo capability to respond to a well-known anti-TNF (infliximab) to assess whether patients’ stratification and monitoring could potentially benefit from such approach.